Our study is also consistent with previous reports that eribulin induced AKT phosphorylation in both preclinical models and in patients’ tumors and that the combination of eribulin and PI3K inhibitors were broadly effective in HER2-negative breast cancer preclinical models regardless of PI3K pathway alterations (48). The gene discussed is AKT1; the disease is breast cancer.